Durante cientos de millones de años, la Tierra fue un mundo dominado por criaturas acuáticas. Pero en un momento crucial de la historia evolutiva, un animal primitivo salió del agua y dio los primeros pasos sobre la tierra firme. Ese pionero fue Tiktaalik, un vertebrado que vivi …
El primer caminante de la historia: así surgió la locomoción a cuatro patas Read More »
La dendrología, la rama de la botánica dedicada al estudio de los árboles y las plantas leñosas, está viviendo un momento crucial. En un escenario global dominado por la crisis climática, los incendios forestales, la pérdida de biodiversidad y la pres …
Dendrología: la ciencia clave para entender y proteger los bosques del futuro Read More »
En los últimos años, la industria de la construcción ha experimentado una transformación que promete cambiar para siempre la forma en que diseñamos y levantamos viviendas. Con el aumento del coste de la vida, la escasez de mano de obra y la urgencia de construir de …
Materiales innovadores que abaratan y aceleran la vivienda del futuro Read More »
With $6 billion left in firepower, Pfizer is planning transactions in the hundreds of millions to the low-billions range, particularly in internal medicine and immunology and inflammation, Guggenheim reported.
Pfizer Is Not a Done Dealmaker After Metsera Buy, With $6B More To Spend Read More »
After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this summer—the lowest they’d been since early 2021. But they now sit higher than they did at the start of the year.
Regeneron Climbs Back After a Year of Regulatory, Manufacturing Misery Read More »
Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.
Japanese Pharmas Looking Beyond Borders for M&A to US, EU Read More »
But more than 300 hospitals didn’t participate in the CMS’ relief program, even though they faced financial disruption — and were more likely to be small and rural facilities, according to Health Affairs research.
Change cyberattack relief funding overpaid many hospitals: study Read More »
Saol Therapeutics received a complete response letter for its pyruvate dehydrogenase complex deficiency treatment a week after the FDA unveiled its Rare Disease Evidence Principles program. On Dec. 18, in a Type A meeting, the biotech will attempt to convince the agency that its drug fits perfectly into the framework.
Saol To Pitch Ultrarare Disease Drug as “Poster Child” for RDEP Program Read More »
Virginia Tenpenny will oversee the hospital operator’s community engagement initiatives, including its social and charitable investments, outreach and strategic partnerships.
Pfizer apparently had more in the tank after the high-profile battle to acquire Metsera earlier this fall. The company has licensed a new GLP-1 from YaoPharma.
After Metsera Battle, Pfizer Heads to China for Another Obesity Deal Worth up to $1.9B Read More »
